Q-omics provides the consensus-scored LRRC18 profile across patient tissues and cancer cell-line models. LRRC18 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC18 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, LRRC18 RNA expression shows 21,480 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, LUSC, and LSCC as cancer lineages where LRRC18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC18 survival associations across molecular data types. LRRC18 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC18 RNA expression–survival associations across cancer types. High LRRC18 expression shows unfavorable associations in ACC, CESC, THCA, KICH and LUSC, but favorable associations in UCEC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC18 RNA expression.
This table summarizes LRRC18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LRRC18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC18 shows lower tumor expression in LUSC, LUAD, COAD, KICH and BLCA and higher tumor expression in STAD. The LUSC box plot shows higher LRRC18 RNA expression in normal versus tumor tissue (log2 FC = −2.008, t-test p < 0.001).
This table shows molecular features associated with LRRC18 in patient tissues and cancer cell lines. In patient samples, LRRC18 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
